Price Movement and Market Context
On 5 December 2025, Vivo Bio Tech . opened with a gain of 2.09%, touching an intraday high of Rs.30.77. However, the stock experienced notable volatility throughout the trading session, ultimately declining to an intraday low of Rs.27.6, which represents an 8.43% drop from the day’s high. This level marks the lowest price point for the stock in the past 52 weeks.
The stock has been on a downward trajectory for the last two consecutive days, with a cumulative return of -5.9% over this period. Today’s decline also underperformed the Pharmaceuticals & Biotechnology sector by 5.04%, indicating relative weakness compared to its industry peers.
Vivo Bio Tech . is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning suggests sustained downward momentum in the stock price over multiple time horizons.
Comparison with Broader Market Trends
While Vivo Bio Tech . has been facing headwinds, the broader market has shown resilience. The Sensex opened lower by 139.84 points but rebounded sharply to close 478.44 points higher, trading at 85,603.92, which is just 0.65% shy of its 52-week high of 86,159.02. The index is supported by bullish moving averages, with the 50-day moving average positioned above the 200-day moving average, signalling a positive market trend overall.
Large-cap stocks have been leading the market rally, contrasting with the underperformance of Vivo Bio Tech ., which is a micro-cap stock within the Pharmaceuticals & Biotechnology sector.
Our current Stock of the Month is out! This Large Cap from Automobiles - Passenger Cars emerged as the single best opportunity from our elite universe. Get the details now!
- - Current monthly selection
- - Single best opportunity
- - Elite universe pick
Financial Performance and Valuation Metrics
Over the past year, Vivo Bio Tech . has recorded a total return of -26.56%, significantly trailing the Sensex’s 4.66% return over the same period. The stock’s 52-week high was Rs.56.9, highlighting the extent of the price decline to the current low of Rs.27.6.
The company’s net sales have shown a compound annual growth rate (CAGR) of -0.84% over the last five years, indicating a contraction in revenue over the medium term. Profit after tax (PAT) for the nine months ended September 2025 stood at Rs.3.27 crore, reflecting a decline of 46.74% compared to the previous period.
Return on capital employed (ROCE) for the half-year was recorded at 7.95%, one of the lowest levels in recent periods. The debtor turnover ratio also declined to 3.54 times, signalling slower collection efficiency.
The company’s ability to service its debt is constrained, with an average EBIT to interest ratio of 1.84, suggesting limited coverage of interest expenses by operating earnings. Return on equity (ROE) averaged 6.60%, indicating modest profitability relative to shareholders’ funds.
Valuation Considerations
Despite the subdued financial performance, Vivo Bio Tech . exhibits a relatively attractive valuation metric, with an enterprise value to capital employed ratio of 0.8. This suggests the stock is trading at a discount compared to historical valuations of its peers within the Pharmaceuticals & Biotechnology sector.
However, the company’s profits have contracted by 45.2% over the past year, which has weighed on investor sentiment and contributed to the stock’s price decline.
Why settle for Vivo Bio Tech .? SwitchER evaluates this Pharmaceuticals & Biotechnology micro-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Shareholding and Market Position
The majority of Vivo Bio Tech .’s shares are held by non-institutional investors, which may influence liquidity and trading patterns. The stock’s micro-cap status within the Pharmaceuticals & Biotechnology sector places it in a distinct category compared to larger, more established companies.
Over the last three years, Vivo Bio Tech . has consistently underperformed the BSE500 index, reflecting ongoing challenges in maintaining competitive performance within the broader market.
Summary of Key Metrics
To summarise, Vivo Bio Tech .’s recent price action culminating in a 52-week low of Rs.27.6 is underpinned by a combination of subdued revenue growth, declining profitability, and valuation discounting. The stock’s technical indicators remain weak, trading below all major moving averages, while the broader market and sector indices have shown relative strength.
Investors monitoring the Pharmaceuticals & Biotechnology sector may note the divergence between Vivo Bio Tech . and larger market trends, as well as the company’s financial metrics that highlight areas of concern in earnings and capital efficiency.
Get 1 year of Weekly Picks FREE when you subscribe to MojoOne. Offer ends soon. Start Saving Now →
